884660-46-2 Usage
Description
N-(6-Fluoro-5-iodo-pyridin-2-yl)-acetamide, also known as FC-4801, is a chemical compound belonging to the class of acetamides. It is characterized by the presence of a fluorine and iodine atom attached to a pyridine ring, which contributes to its unique chemical properties and potential applications.
Uses
Used in Pharmaceutical Industry:
N-(6-Fluoro-5-iodo-pyridin-2-yl)-acetamide is used as a building block in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new medicines with potential therapeutic applications.
Used in Agrochemical Industry:
FC-4801 is also used in the agrochemical industry for the synthesis of various agrochemicals, contributing to the development of new products for agricultural applications.
Used in Medicinal Chemistry Research:
N-(6-Fluoro-5-iodo-pyridin-2-yl)-acetamide is used in the field of medicinal chemistry for the synthesis of novel heterocyclic structures. These structures have potential therapeutic applications and can lead to the discovery of new drugs and treatments.
Used in Biological Activity Studies:
FC-4801 exhibits potential biological activity and is being studied for its potential use in the development of new medicines. This research can help identify new therapeutic targets and advance the understanding of the compound's effects on biological systems.
Check Digit Verification of cas no
The CAS Registry Mumber 884660-46-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,4,6,6 and 0 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 884660-46:
(8*8)+(7*8)+(6*4)+(5*6)+(4*6)+(3*0)+(2*4)+(1*6)=212
212 % 10 = 2
So 884660-46-2 is a valid CAS Registry Number.
884660-46-2Relevant articles and documents
FACTOR XIa INHIBITORS
-
, (2016/11/02)
The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.